Clinical trials: Aggressive Behavior, open to volunteers
Aggression, Critical Care Staff
Intensive Care Unit Conflict Mediation Study
To evaluate the impact of a structured, multidisciplinary conflict management program incorporating an interprofessional Singular Care Plan *PAS* Committee and a Conflict Mediation Team on the incidence and severity of conflicts…
- Conditions
- Aggression, Critical Care Staff, Workplace Violence
- Trial name
- "GIRAFFE" (NCT07621874)
- Testing
- SEM DESTINO
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Hospital Israelita Albert Einstein
Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma
First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma
ths study consist in testing a CAR T therapy (ARI0003 cells (antiCD19 and antiBCMA) in patients suffering relapsed NHL (that means that symptoms of NHL reappeared ) or refractory (that means that they did not respond to other…
- Trial name
- CARTD-BG-1 (NCT06097455)
- Testing
- ARI0003
- Where
- 7 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Human Values-Oriented Cyberbullying Prevention Program
The Effect on Adolescents' Cyberbullying/Cyber Victimization and Coping Skills of the Human Values-Oriented Cyberbullying Prevention Program
The aim of this study is to determine the effect of the human values-oriented cyberbullying prevention program on adolescents' cyberbullying/cyber victimization and coping skills.
- Trial name
- NCT07443748
- Testing
- Human Values-Oriented Cyberbullying Prevention Program
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Pelin Büyüksandıç Özşen
Pancreatic Neuroendocrine Tumors (pNET), Pancreatic Neuroendocrine Tumors
Adjuvant Trial in Pancreatic Neuroendocrine Tumors
ADJUPANET is an open label, double arm, multicenter, phase 3 trial that aims to investigate the efficacy of systemic chemotherapy in locally resected aggressive pancreatic neuroendocrine tumors.
- Trial name
- ADJUPANET (NCT07591493)
- Testing
- Adjuvant chemotherapy with Capecitabine-Temozolomide, Active surveillance
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Anger Problems, Aggression
Treatment of Chronic Anger and Aggression Following Military-Related Betrayal
The goal of this clinical trial is to learn if a treatment designed to deal with anger and aggression from a past betrayal will work. The study will be done on active duty military service members and veterans aged 18 or older.
- Trial name
- CART (NCT06609330)
- Testing
- Countering Chronic Anger and Aggression Related to Trauma and Transgressions (CART)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma
Patients with multiple myeloma experience a wide range of physical and psychological symptoms from the time of their diagnosis. Meanwhile, patients with aggressive lymphomas undergo unpredictable illness courses, resulting in…
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Multiple Myeloma Stage III, Multiple Myeloma Progression
- Trial name
- EPC-MM+L (NCT06485076)
- Testing
- Early Palliative Care
- Where
- Canada
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Endometrial Cancer
An Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian Federation
Multicenter, observational, prospective study of molecular profiling in advanced and aggressive endometrial cancer patients and 1-st line treatment approaches in Russian Federation
- Trial name
- IREN (NCT07041606)
- Where
- 19 sites in Russia
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Aggression
The Use of Transcranial Direct Current Stimulation (tDCS) in Adults With Developmental Disabilities
Aggressive behaviours are highly prevalent among people with developmental disabilities, both in community and inpatient or residential settings, with adverse consequences for the individuals involved and others.
- Trial name
- tDCS-RIADD (NCT04732052)
- Testing
- Transcranial Direct Current Stimulation
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Dr. Najat Khalifa
Violence, Adolescent
Addressing Root Causes for Gun Violence Prevention (ARC-GVP)
The goal of this study is to help build the evidence base for a locally-relevant youth firearm violence prevention program in Washington D.C., a city experiencing disparities in youth firearm violence outcomes.
- Conditions
- Violence, Adolescent, Firearm Injury, Aggression
- Trial name
- NCT05887973
- Testing
- The T.R.I.G.G.E.R Project
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- University of Michigan
T Cell Lymphoma, T-cell Lymphoma
Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
Single-arm Phase II study evaluating the combination of mogamulizumab (MOGA) added on top of standard of care dose adjusted EPOCH (DA-EPOCH) or CHOEP in patients with newly diagnosed or relapsed/refractory (for CTCL only)…
- Trial name
- NCT05996185
- Testing
- Mogamulizumab, DA-EPOCH Protocol, CHOEP protocol
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Yale University
Autism, Intellectual Disabilities With Other Behavioral Symptoms
Regulating Together for Intellectual Disability and Autism: A Group Behavioral Therapy for for Emotion Dysregulation
The goal of this study is to help children with autism and a co-occurring intellectual disability and their families learn practical strategies for managing issues like irritability, aggression, and other challenging behaviors.
- Conditions
- Autism, Intellectual Disabilities With Other Behavioral Symptoms, Intellectual Disability
- Trial name
- RT-ID (NCT07624448)
- Testing
- Regulating Together group therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Children's Mercy Hospital Kansas City
Aggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL)
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
This is a phase II study designed to evaluate the toxicity and efficacy of the combination of loncastuximab tesirine and epcoritamab in patients with relapsed/refractory aggressive B-cell lymphoma.
- Conditions
- Aggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL), Follicular Lymphoma (FL) Grade 3B
- Trial name
- CLEAR (NCT07197307)
- Testing
- Loncastuximab Tesirine and Epcoritamab
- Where
- 34 sites in Germany
- Volunteers
- 120 people
- Sponsor
- Universität Münster
Child Behavior Problem, Disruptive Behavior
Step-by-Step: Evaluation of a Stepped Care Model
The primary aim of this project is to examine the effectiveness of a stepped care model of interventions for children's defiant or aggressive behavior problems.
- Conditions
- Child Behavior Problem, Disruptive Behavior, Oppositional Defiant Disorder, Conduct Problems
- Trial name
- NCT06902649
- Testing
- Internet-based parenting support, "YourSkills" for children/youth, Step-by-step parent support
- Where
- Sweden
- Volunteers
- 210 people
- Sponsor
- Karolinska Institutet
Relapsed/Refractory Aggressive B-Cell Lymphoma
Clinical Study of SYS6055 Injection in Participants With Relapsed/Refractory Aggressive B-Cell Lymphoma
This is a Phase I/II clinical study conducted in participants with relapsed/refractory aggressive B-cell lymphoma. The study aims to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of…
- Trial name
- NCT07476066
- Testing
- SYS6055
- Volunteers
- 374 people
- Sponsor
- Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd
Extranodal NK/T-cell Lymphoma, Aggressive NK-Cell Leukemia
Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases
This is a multicenter, non-interventional, ambidirectional cohort study of Epstein-Barr virus-positive T/NK-cell lymphoproliferative diseases.
- Conditions
- Extranodal NK/T-cell Lymphoma, Aggressive NK-Cell Leukemia, Systemic Chronic Active Epstein-Barr Virus Disease, Epstein-Barr Virus-Positive Nodal T/NK-Cell Lymphoma
- Trial name
- EBV-T/NK Cohor (NCT07727083)
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Rong Tao
Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
This phase II trial tests the effectiveness of golcadomide and rituximab as bridging treatment before chimeric antigen receptor (CAR) T-cell therapy in patients with aggressive B-cell non-Hodgkin lymphoma that has come back after…
- Conditions
- Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent ALK-Positive Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
- Trial name
- NCT06834373
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 7 sites in United States
- Volunteers
- 41 people
- Sponsor
- Mayo Clinic
Endocrine Tumor
A Research Registry on Aggressive PitNETs
To allow the identification of markers, it is necessary to extend research networks more widely to collect and properly explore aggressive pituitary tumours.
- Trial name
- RECAPitNETT (NCT05974696)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Hospices Civils de Lyon
Alzheimer Disease, Agitation in Dementia
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
The purpose of this research study is to test if adding one infusion of mesenchymal stem cells to the current treatment with antipsychotic medication may help control behavioral problems in people with a diagnosis of moderate to…
- Trial name
- NCT06781333
- Testing
- hMSC
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Bernard (Barry) Baumel
Prostate Cancer
Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration
A multicentre observational study on treatment patterns and ctDNA HRR evaluation in aggressive high-volume metastatic hormone-sensitive prostate cancer in Russian Federation
- Trial name
- CONCORD (NCT07052578)
- Where
- 28 sites in Russia
- Volunteers
- 230 people
- Sponsor
- AstraZeneca
Cancer
Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses
This is a prospective, open-label navigational investigation designed to evaluate the feasibility of using molecular profile-based evidence to determine individualized cancer therapy for patients with aggressive malignancies.
- Trial name
- MCW I-PREDICT (NCT05674825)
- Testing
- Targeted agent, Standard of care agent
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Medical College of Wisconsin